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Introductory Chapter:  




The current trend in medicine divides into two aspects of treatment - preventive 
medicine and regeneration of damaged tissues (regenerative medicine) [1]. One of 
goals of regenerative medicine is to improve wound healing without major surgical 
procedures and donor-site morbidity. This may be obtained by cell-based therapy 
[2]. The potential to restore tissue to its pre-injured state may be achieved by novel 
therapeutic modalities, including stem cells. Stem cells have been proposed for 
the treatment and management of variety of diseases in recent years. In PubMed 
366,445 results occur when stem cells phrase is searched, including 5,547 publica-
tions describing clinical trials (Figure 1).
2. Current knowledge
There is still much to know about stem cells. How they differentiate? Why some 
therapies may not be effective? How can we use stem cells in other way? Latest 
studies shown that shape change may be indicator of cell’s exit from pluripotency 
and prevention of release cell membrane from actin cortex may prevent cells 
from differentiation [3]. It is know that microenvironment impact cells responses 
which direct tissue growth and physiology [4]. Influencing cell responsiveness may 
Figure 1. 
Stem cell studies and research development during over 100 years.
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enhance the regenerative potential of stem cells and therefore improve therapies. 
Combination of mechanobiological factors can support MSCs to promote vascular 
regeneration, enhancing endogenous regeneration differentiating them to cell 
types crutial in neoangiogenesis [5]. But may stem cells be answer in whole organs 
regeneration or transplantation? Organoids, which are multicellular structures 
consisting of organ-specific cells are widely created not only to understand organo-
genesis and disease progression but also in order to potentially treat organ failure 
[6]. Unfortunately obtaining full organ from stem cells will be impossible for next 
few decades as organoids made from stem cells are highly simplified [7]. However in 
other clinical fields stem cells therapies has been widely used for many years.
3. The source
The sources of stem cells for different therapies may vary. Different types of 
stem and progenitor cells can be isolated from different perinatal tissues, making 
them particularly interesting candidates for use in cell therapy and regenerative 
medicine. The main source of perinatal stem cells is cord blood. Cord blood has 
been a well-known source of hematopoietic stem/progenitor cells since 1974. For 
over 30 years, umbilical cord blood obtained from biobanks has been used in the 
treatment of various hematological and immune disorders. Other perinatal tissues 
that are routinely discarded as medical waste contain non-hematopoietic cells of 
potential therapeutic value. Indeed, mesenchymal stromal cells are most commonly 
used in advanced research into perinatal cell therapy [8]. In this perspective, the 
placenta may deserve special attention [9]. The placenta is a temporary organ that 
is ejected after birth and is one of the most promising sources of various cells and 
tissues for use in regenerative medicine and tissue engineering, both experimental 
and clinical. The placenta has unique intrinsic features because it plays many roles 
during pregnancy: it is formed by the cells of two people (mother and fetus), 
contributes to the development and growth of an allogeneic fetus, and has two 
independent and interacting circulatory systems [8, 9]. The application of MSCs 
isolated from the amniotic membrane on the acelular dermal matrix ADM allowed 
for complete healing of extensive wounds of the burned patient without the need to 
perform an autologous skin transplant [10] which may be a game changer in burn 
treatment therapy.
4. Clinical applicability
Stem cells are used not only to support wound healing. Stem cells transplanta-
tion in patients with multiple sclerosis and amyotrophic lateral sclerosis was a 
clinically feasible and relatively safe procedure that produces an immediate immu-
nomodulatory effect [11]. Interesting results for the treatment of autism were pre-
sented in an open-label Phase I trial. Ongoing inflammation of the nervous system 
may contribute to the symptoms of autism spectrum disorder (ASD). Mesenchymal 
stromal cells (MSCs) have been shown to modulate inflammation in the nervous 
system [12]. Another interesting application of MSCs may be in the future the use 
of their potential to modulate the immune response during immunosuppressive 
therapy. Stem cells have been shown to modulate the action of immunosuppres-
sants, and when combined with immunosuppressants, they have a pronounced 
effect on cell activation and the balance between different T cell subpopulations 
and exert an inhibitory effect on pro-inflammatory T cell subsets while promoting 
anti-inflammatory Treg cell function. MSC-based therapy has been shown to be a 
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powerful strategy to mitigate the negative effects of immunosuppressive drugs on 
the immune system [13]. Those therapies may cause concern about safety but many 
clinical trials has been studying the safeness and efficacy of mesenchymal stem cells 
therapies. Most recent describes Phase 1 trial for treatment of COVID-19 patients 
with pulmonary fibrosis using hESC-IMRCs [14] in which none of the treated 
patients suffered any adverse events or abnormal responses related to cell therapy. 
This suggest that stem cell therapies has become more and more safe, popular and 
researchers discover every year new potential fields of treatment with usage of 
stem cells.
5. Possibilities
Where else stem cells can be used if not for transplantation? Another option is to 
study evolutionarily conserved mechanisms with usage of interspecies pluripotent 
stem cell (PSC) co-culture. This mode enables uncovered a unknown competitive 
cell interaction during early mammalian development [15].
Stem cells show ourselves many possibilities and when we start think that we 
know already something a whole new branch of research opens thanks to this 
unique cells. This book guides us through stem cell types, therapy possibilities, law 
and ethical aspects. It is complete source of knowledge which is base of further 
research.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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